Overview of randomised trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure
Garg R.G., Yusuf S. Overview of randomised trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 273:1995;1450-1456.
Effect of enalapril on survival in patients with reduced left ventricular ejections fraction and congestive heart failure
Effect of enalapril on survival in patients with reduced left ventricular ejections fraction and congestive heart failure. N Engl J Med. 325:1991;293-302.
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the survival and ventricular enlargement trial
Pfeffer M.A., Braunwald E., Moyé L.A.et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med. 327:1992;669-677.
Prolongation of survival in congestive cardiomyopathy by β-receptor blockade
Swedberg K., Hjalmarson Å., Waagstein F., Wallentin I. Prolongation of survival in congestive cardiomyopathy by β-receptor blockade. Lancet. i:1979;1374-1376.
Influence of heart size on mortality and reinfarction in patients treated with timolol after myocardial infarction
Gundersen T. Influence of heart size on mortality and reinfarction in patients treated with timolol after myocardial infarction. Br Heart J. 50:1983;135-139.
Effect of propranolol after acute myocardial infarction in patients with congestive heart failure
Chadda K., Goldstein S., Byington R., Curb J.D. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation. 73:1986;503-510.
The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
Packer M., Bristow M.R., Cohn J.N.et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334:1996;1349-1355.
Metoprolol prevents left ventricular dilatation and increase exercise ejection fraction to the same extent in idiopathic and ischemic cardiomyopathy
abstr
Waagstein F., Wahlqvist I., Andersson B.et al. Metoprolol prevents left ventricular dilatation and increase exercise ejection fraction to the same extent in idiopathic and ischemic cardiomyopathy. Eur Heart J. 19(suppl):1998;307. abstr.
Mode of death in chronic heart failure. a request and proposition for more accurate classification
Narang R., Cleland J.G.F., Erhardt L.et al. Mode of death in chronic heart failure. a request and proposition for more accurate classification. Eur Heart J. 17:1996;1390-1403.
Beta-blocking agents in heart failure: Should they be used and how?
Cleland J.G.F., Bristow M.R., Erdmann E., Remme W.J., Swedberg K., Waagstein F. Beta-blocking agents in heart failure: should they be used and how? Eur Heart J. 17:1996;1629-1639.
Effects of beta-blocker therapy on mortality in patients with heart failure
Doughty R.N., Rodgers A., Sharpe N., MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure. Eur Heart J. 18:1997;560-565.
Effect of beta-blockade on mortality in patients with heart failure: A meta-analysis of randomized clinical trials
Heydenrich P.A., Lee T.T., Massie B.M. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol. 30:1997;27-34.
Arrhytmias and sudden death in heart failure: Can we prevent them?
J.J.V. McMurray, & J.G.F. Cleland. London: Martin Dunitz Ltd
Rankin A.C., Cobbe S.M. Arrhytmias and sudden death in heart failure: can we prevent them? McMurray J.J.V., Cleland J.G.F. Heart failure in clinical practice. 1996;189-205 Martin Dunitz Ltd, London.
Metoprolol-induced reduction in postinfarction mortality: Pooled results from five double-blind randomized trials
Olsson G., Wikstrand J., Warnold I.et al. Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. Eur Heart J. 13:1992;28-32.
Primary prevention of sudden cardiovascular death in hypertensive patients: Mortality results from the MAPHY study
Olsson G., Tuomilehto J., Berglund G.et al. Primary prevention of sudden cardiovascular death in hypertensive patients: mortality results from the MAPHY study. Am J Hypertens. 4:1991;151-158.
Extended release metoprolol CR/XL in patients with heart failure: A pilot study examining the tolerability, safety and effect on left ventricular ejection fraction
in press
Goldstein S., Kennedy H.L., Hall C.et al. Extended release metoprolol CR/XL in patients with heart failure: a pilot study examining the tolerability, safety and effect on left ventricular ejection fraction. Am Heart J. 1999;. in press.
Design of a new multiple-unit controlled-release formulation of metoprolol: Metoprolol CR/XL
Sandberg A., Ragnarsson G., Jonsson U.E., Sjögren J. Design of a new multiple-unit controlled-release formulation of metoprolol: metoprolol CR/XL. Eur J Clin Pharmacol. 33(suppl):1988;S3-7.
The effect on heart rate of immediate and slow-release metoprolol in patients with chronic heart failure
abstr
Andersson B., Åberg J. The effect on heart rate of immediate and slow-release metoprolol in patients with chronic heart failure. J Am Coll Cardiol. 33:1999;183-184A. abstr.
Effect of metoprolol on the prognosis for patients with suspected acute myocardial infarction and indirect signs of congestive heart failure (A subgroup analysis of the Göteborg Metoprolol Trial)
Herlitz J., Waagstein F., Lindqvist J., Swedberg K., Hjalmarson Å. Effect of metoprolol on the prognosis for patients with suspected acute myocardial infarction and indirect signs of congestive heart failure (A subgroup analysis of the Göteborg Metoprolol Trial). Am J Cardiol. 80:1997;40-44J.
Similar risk reducing effect of extended release metoprolol once daily and immediate release metoprolol twice daily during 5 years after myocardial infarction
in press
Herlitz J., Dellborg M., Karlson B.W.et al. Similar risk reducing effect of extended release metoprolol once daily and immediate release metoprolol twice daily during 5 years after myocardial infarction. Cardiovasc Drugs Ther. 1999;. in press.